Physician profile
Qing Ren
NPI 1316137722
$1,705.16
in general payments reported to CMS, 2019-2025
20 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $114 · 2021: $98.51 · 2022: $155 · 2023: $405 · 2024: $355 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $356.24 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $207.57 | 2019-2025 | |
| Vifor Pharma, INC. | $173.84 | 2019-2024 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $172.11 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $168.78 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $104.41 | 2023-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $103.34 | 2023-2024 | |
| Ardelyx, INC. | $72.07 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $57.45 | 2020-2022 | |
| Lilly USA, LLC | $49.02 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $43.64 | 2023-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $31.70 | 2020-2021 | |
| Outset Medical INC | $27.57 | 2023 | |
| Horizon Therapeutics Plc | $25.48 | 2019-2022 | |
| Akebia Therapeutics INC | $23.19 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $21.89 | 2019 | |
| Amgen INC. | $18.87 | 2019 | |
| Shield Therapeutics INC | $18.00 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $15.14 | 2019 | |
| Aurinia Pharma U.S., INC. | $14.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Ren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.